ClinicalTrials.gg
CompletedNCT02654171VICTORUpdated Feb 20, 2024

Viral Inhibition in Children for Treatment of RSV

A Phase 2 interventional study of AK0529 and Placebo in RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 28 sites in 8 countries. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
1 Month to 24 Months
Sex
All
01

Study summary

VICTOR is a randomized, double-blind, placebo-controlled, multicenter, 2-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effect of single and multiple dosing of AK0529 in infants hospitalized with RSV infection.

Read the detailed description

Globally, Respiratory Syncytial Virus (RSV) is recognized as the leading cause of respiratory tract infections in infants and young children and a major cause of hospitalization due to severe respiratory infection. Despite four decades of effort, there are still no effective methods to control RSV infection. Treatment of RSV has been limited to supportive measures. There is an urgent need for safe and effective drugs to treat and prevent RSV disease.

AK0529 is an investigational antiviral agent that targets the RSV fusion protein on the surface of the viral envelope and exerts antiviral activity against RSV by inhibiting viral entry into host cells and preventing fusion protein induced cell-cell fusion. AK0529 was generally well tolerated in healthy volunteers.

This study is designed as a randomized, double-blind, placebo-controlled, multicenter, phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effect of single and multiple dosing of AK0529 in infants hospitalized with RSV infection. It will consist of two parts, Part 1 and Part 2. Each part will consist of three phases, a pre-treatment phase, a treatment phase and post-treatment follow-up phase.

02

Conditions studied

  • RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Keywords

  • RSV
  • AK0529
03

In context

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

This study's enrollment of 72 is below the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.

Browse Respiratory Syncytial Virus Infections studies →

Lead sponsor

Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients of any race or ethnicity with an age adjusted for any prematurity of ≥1 month and ≤24 months.
  • Diagnosis of RSV infection by virological means, which may include rapid diagnostic point-of-care testing, within 96 hours preceding screening for Part 1 and 72 hours for Part 2.
  • Patient must weigh >3 kg at screening and be within the 10th and 90th percentiles (inclusive) for the patient's age, based on the local child growth standards, i.e. the Australian Paediatric Endocrine Group Growth Charts.
  • The parent / legal guardian of the patient must have provided written for the patient to participate.
  • For patients aged \<12 months, an occipito-frontal head circumference within the normal range for age and gender.

Exclusion criteria

Exclusion Criteria:

  • The patient has taken, is currently taking or requires any restricted medications.
  • Patient is known to be -positive (or the mother, if the potential patient is a child aged \<6 months).
  • Participation in an drug or device study within 30 days prior to the date of screening.
  • Requires vasopressors or inotropic support at the time of enrolment.
  • Concurrent gastrointestinal conditions that could, in the opinion of the investigator, prejudice absorption of the Investigational Medicinal Product (e.g. protracted vomiting, malabsorption syndrome, a history of necrotising enterocolitis with consequent short gut syndrome).
  • Bronchopulmonary dysplasia or chronic lung disease requiring assisted ventilation at the time of enrolment.
  • Diminished ventilatory reserve at risk for hypercapnia (e.g. pulmonary hypoplasia, sequestration syndromes, cystadenomatoid malformation, a history of surgery for diaphragmatic hernia).
  • Left to right shunt meriting corrective therapy.
  • Renal failure including renal anomalies likely to be associated with renal insufficiency (e.g. clinical conditions of renal dysplasia, polycystic renal disease, renal agenesis).
  • Clinical evidence of hepatic decompensation (e.g. hepatic disorder with associated coagulopathy or associated encephalopathy).
  • Cerebral palsy with microcephaly, chronic or persistent feeding difficulties or seizures.
  • Symptomatic because of inborn errors of metabolism (e.g. mitochondrial disorders, disorders of carbohydrate metabolism, glycogen storage disorders).
  • Congenital or acquired immunodeficiency (e.g. congenital agammaglobulinaemia, common variable immunodeficiency, therapy other than or montelukast therapy forming part of care directed by the treating physician).
  • For Part 2 of this study, children with a history of having received palivizumab or any other monoclonal agent directed against RSV in the preceding 120 days. This exclusion criterion does not apply to Part 1.
  • Evidence of active or uncontrolled respiratory, cardiac, hepatic, central nervous system or renal disease unrelated to RSV infection at baseline or any other medical condition that in the opinion of the investigator renders the patient unsuitable for enrolment.
  • A history of epilepsy or seizures including febrile seizures.
  • Allergy to test medication or constituents.
  • Weight less than 10th percentile or greater than 90th percentile for age and gender adjusted for any prematurity.
  • The patient's parent or legally acceptable representative is an employee of the investigator or the study center, with direct involvement in the proposed study or other studies under the direction of that investigator of the study center, or any family members of the employees or the investigator.
  • Failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    AK0529

    Subjects will receive single or multiple doses of AK0529 at different dose levels within different cohorts.

    Drug: AK0529

  • Placebo comparator
    Placebo

    Patients who are randomized to the control arm within each cohort will receive the corresponding placebo to AK0529.

    Drug: Placebo

Interventions

  • DrugAK0529

    AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.

  • DrugPlacebo

    The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events during the study

    Time frame: Day -4 to single dose Day 7 (Part 1) and Day -3 to multiple dose Day 14 (Part 2)

  2. Subject withdrawals due to Adverse Events

    Time frame: Day -4 to single dose Day 7 (Part 1) and Day -3 to multiple dose Day 14 (Part 2)

Secondary outcomes

  1. Area under the plasma concentration-time curve from time 0 to infinity (AUC)

    For patients without intravenous cannulation, samples will be collected at pre-dose, 2, 6 and 12 hours post-dose on Day 1.

    Time frame: Pharmacokinetic samples will be taken predose, 2, 4, 6, 12, 18, 24 hours postdose on Day 1, 48 hours postdose (Part 1 and Part 2) and Day 5 (Part 2 )

  2. Maximum plasma concentration of AK0529 (Cmax)

    For patients without intravenous cannulation, samples will be collected at pre-dose, 2, 6 and 12 hours post-dose on Day 1.

    Time frame: Pharmacokinetic samples will be taken predose, 2, 4, 6, 12, 18, 24 hours postdose on Day 1, 48 hours postdose (Part 1 and Part 2) and Day 5 (Part 2 )

  3. Plasma concentration of AK0529 at 12 hours postdose (C12)

    For patients without intravenous cannulation, samples will be collected at pre-dose, 2, 6 and 12 hours post-dose on Day 1.

    Time frame: Pharmacokinetic samples will be taken predose, 2, 4, 6, 12, 18, 24 hours postdose on Day 1, 48 hours postdose (Part 1 and Part 2) and Day 5 (Part 2 )

  4. Apparent total body clearance (CL/F)

    For patients without intravenous cannulation, samples will be collected at pre-dose, 2, 6 and 12 hours post-dose on Day 1.

    Time frame: Pharmacokinetic samples will be taken predose, 2, 4, 6, 12, 18, 24 hours postdose on Day 1, 48 hours postdose (Part 1 and Part 2) and Day 5 (Part 2 )

  5. Apparent central compartment volume of distribution (Vc/F)

    For patients without intravenous cannulation, samples will be collected at pre-dose, 2, 6 and 12 hours post-dose on Day 1.

    Time frame: Pharmacokinetic samples will be taken predose, 2, 4, 6, 12, 18, 24 hours postdose on Day 1, 48 hours postdose (Part 1 and Part 2) and Day 5 (Part 2 )

  6. Area under curve change of viral load

    The antiviral effects in infants hospitalized with RSV are to be determined by measuring the RSV viral load area under the curve in nasal, pharyngeal and tracheal washes / aspirates from baseline to last administration of study medication (Day 5).

    Time frame: From baseline to Day 5

  7. Incidence of F-protein genotypes

    The incidence of F-protein genotypes associated with reduced sensitivity to IMP will be evaluated.

    Time frame: Specimen will be collected predose and 24 hours postdose on Day 1 (Part 1) and on Day 1-5 (Part 2).

  8. Change of symptom score

    To evaluate the change of RSV related symptom score in AK0529 arms compared with the change in placebo arm after treatment. The total score is reported with a range from 0 to 12. A decreasing value of total score represents clinical improvement. Subscales are not applicable in this symptom score.

    Time frame: From baseline to Day 1 (Part 1) and up to Day 5 after multiple drug administration (Part 2).

07

Study locations

28 sites
  • Gold Coast University Hospital
    Gold Coast, Queensland, Australia
  • Lady Cilento Children's Hospital
    South Brisbane, Queensland 4101, Australia
  • Women's and Children's Hospital
    Adelaide, South Australia, Australia
  • Prince of Wales Hospital
    Sha Tin, Hong Kong
  • Soroka University Medical Center
    Beer-Sheva, Israel
  • Ruth Rappaport Children's Hospital
    Haifa, Israel
  • Schneider Children's Medical Center
    Petach Tikvah, Israel
  • American University of Beirut Medical Center
    Beirut, Lebanon
  • Makassed General Hospital
    Beirut, Lebanon
  • Rafik Hariri University Hospital
    Beirut, Lebanon
  • Saint George Hospital University Medical Center
    Beirut, Lebanon
  • Hospital Tuanku Jaafar
    Seremban, Negeri Sembilan, Malaysia
  • Hospital Sibu
    Sibu, Sarawak, Malaysia
  • Hospital Selayang
    Batu Caves, Selangor, Malaysia
  • Hospital Tengku Ampuan Rahimah
    Klang, Selangor, Malaysia
  • University Malaya Medical Center
    Kuala Lumpur, Malaysia
  • Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem w Poznaniu
    Poznań, Greater Poland, Poland
  • Nowy Szpital w Świeciu
    Świecie, Kujawy-Pomerania, Poland
  • Szpital im. Świętej Jadwigi Śląskiej w Trzebnicy
    Trzebnica, Trzebnica County, Poland
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, Taiwan
  • Mackay Memorial Hospital
    Taipei, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Municipal Wanfang Hospital
    Taipei, Taiwan
  • Linkou Chang Gung Memorial Hospital
    Taoyuan, Taiwan
  • Cukurova University Balcali Hospital
    Adana, Adana Province, Turkey
  • Eskisehir Osmangazi University Faculty of Medicine
    Eskişehir, Eskişehir Province, Turkey
  • Ege University Medical Faculty
    İzmir, İzmir Province, Turkey
  • Marmara University Faculty of Medicine
    İstanbul, Turkey
08

References and documents

Publications

  • Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1. PubMed 20399493 ↗
  • Huang LM, Schibler A, Huang YC, Tai A, Chi H, Chieng CH, Wang JL, Goldbart A, Tang SP, Huang YC, George S, Alabaz D, Bentur L, Su SC, de Bruyne J, Karadag B, Gu F, Zou G, Toovey S, DeVincenzo JP, Wu JZ. Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trial. Influenza Other Respir Viruses. 2023 Jul 25;17(7):e13176. doi: 10.1111/irv.13176. eCollection 2023 Jul. PubMed 37502622 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Mar 2019, 34 months.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 34 months is above that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2016
First posted
Jan 13, 2016
StartActual
May 27, 2016
Primary completionActual
Mar 31, 2019
CompletionActual
Apr 9, 2019
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02654171
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Collaborators
Ark Biosciences Pty Ltd.
Responsible party
Sponsor
First posted
Jan 13, 2016
Start date
May 27, 2016
Primary completion
Mar 31, 2019
Completion
Apr 9, 2019
Last update
Feb 20, 2024

Study contacts

Ark Clinical Trial
study director · info@arkbiosciences.com

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion